Companies Investors People

Loading

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

Get in Touch

Contact
Request a Demo
Request Data Updates
Add a Company

Research

Companies
Investors
People

aVenture

Download App
Pricing

Resources

Documentation
Use Cases
CLI
MCP
Feature Requests
Sitemap

Member

Backed by

Ask AI about aVenture

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy · Terms of Service

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading

Arie Belldegrun - aVenture Research

Arie Belldegrun

AddedMar 31, 2024

UpdatedOct 13, 2026

Arie Belldegrun

Arie Belldegrun

Founder, Kite Pharma

Arie Belldegrun's Career

Allogene Therapeutics

Arie Belldegrun's Co-Investors

John C. MartinCo-invested · Kronos Bio Seed

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview

aVenture product preview

aVenture product preview

Arie Belldegrun's Investments

2 investments since 2014

1 operating · 1 acquired

Investments view

Group by

2019

1

Kronos Bio
Series A · July 2019$105M
Series A · July 2019

2014

1

Kite Pharma
Debt · May 2014$50M
Debt · May 2014

Public$781.8MSouth San Francisco, CA, US

Executive Chairman

Board Member· Board

Kite Pharma

$12.2BSanta Monica, CA, US

Founder

President and Chief Executive Officer

Pontifax

Investment FirmHerzliya, Tel Aviv District, IL

Board Member· Board

Bellco Capital

Investment FirmLos Angeles, CA, US

Board Member· Board

Two River

Investment FirmNew York City, NY, US

Board Member· Board

UroGen Pharma

Public$422.1MNew York City, NY, US

Board Member· Board

Kronos Bio

Public$278MSan Mateo, CA, US

Board Member· Board

Ginkgo Bioworks

Public$1.6BBoston, MA, US

Board Member· Board

People Similar to Arie Belldegrun

David BondermanCo-Founder · TPG Capital Asia

Todd SisitskyBoard Member · Allogene Therapeutics

Leadership at Allogene Therapeutics

David ChangFounder

Liz BarrettBoard Member

Stephen L. MayoBoard Member

Debbie MessemerBoard Member

Owen WitteBoard Member

John DeYoungBoard Member

Similar to Allogene Therapeutics

Senti BiosciencesSouth San Francisco, CA, USCancer Therapiesest. 2016Senti BiosciencesSouth San Francisco, CA, US · est. 2016

Senti Biosciences: Innovating cell-based, programmable cancer therapies.

Public · $215.9M122

Leadership at Kite Pharma

Franz HumerBoard Member

David Bonderman "Bondo"Board Member

Dr Owen N WitteBoard Member

Similar to Kite Pharma

Chimera BioengineeringSouth San Francisco, CA, USCancer Treatmentest. 2015Chimera BioengineeringSouth San Francisco, CA, US · est. 2015

Innovative cancer treatment firm harnessing CARs technology to boost immune response against tumors.

Series B · $30.7M18

Deciphera PharmaceuticalsWaltham, MA, USCancer Treatmentsest. 2003Deciphera PharmaceuticalsWaltham, MA, US · est. 2003

US-based Deciphera Pharmaceuticals develops kinase inhibitor treatments for various cancers globally.

Immpact BioCamarillo, CA, USCAR T-Cell Therapyest. 2017Immpact BioCamarillo, CA, US · est. 2017

ImmPACT Bio: Innovating transformative CAR-T cell therapies for advanced cancer patients.

Series B · $129M105

Iovance BiotherapeuticsSan Carlos, CA, USCancer Therapiesest. 2007Iovance BiotherapeuticsSan Carlos, CA, US · est. 2007

Iovance Biotherapeutics: A California-based biotech firm specializing in novel cancer immunotherapies.

Leadership at Pontifax

Ran NussbaumCo-Founder

Tomer KarivCo-Founder & CEO

Similar to Pontifax

Forepont Capital PartnersNew York City, NY, USest. 2014Forepont Capital PartnersNew York City, NY, US · est. 2014

Forepont Capital Partners: Providing permanent capital and strategic support to US and EU tech-health startups since 2014.

Investment Firm12

Pfizer Venture InvestmentsNew York City, NY, USest. 2004Pfizer Venture InvestmentsNew York City, NY, US · est. 2004

Pfizer Venture Investments: A strategic life science VC, investing in transformative medicines and technologies.

Investment Firm30

PontaqLondon, Greater London, GBest. 2015PontaqLondon, Greater London, GB · est. 2015

Pontaq: A UK-based venture capital fund fostering cross-border tech transfer and job creation.

Investment Firm9

Pivotal bioVenture Partners ChinaShanghai, CNest. 2017Pivotal bioVenture Partners ChinaShanghai, CN · est. 2017

Pivotal bioVenture Partners China: A venture capital firm innovating in life sciences.

Investment Firm7

Leadership at Bellco Capital

Rebecka BelldegrunCEO

Similar to Bellco Capital

Belle CapitalDouglas, AZ, USest. 2013Belle CapitalDouglas, AZ, US · est. 2013

Belle Capital LP: A US-based venture capital firm investing in mobile, internet, IT, life sciences, and clean tech sectors.

Investment Firm175

Marc Bell CapitalBoca Raton, FL, USest. 2003Marc Bell CapitalBoca Raton, FL, US · est. 2003

Marc Bell Capital: A Florida-based private equity firm specializing in diverse investments, primarily in commercial and real estate sectors.

Investment Firm30

Corbel Capital PartnersLos Angeles, CA, USest. 2013Corbel Capital PartnersLos Angeles, CA, US · est. 2013

LA-based Corbel Capital Partners is a private equity firm specializing in non-control consumer and retail investments.

Investment Firm24

Colbeck Capital ManagementNew York City, NY, USest. 2009Colbeck Capital ManagementNew York City, NY, US · est. 2009

Colbeck Capital Management, LLP: A private credit manager specializing in distressed debt and strategic lending.

Investment Firm22

Leadership at Two River

David TanenCo-Founder

Joshua KazamCo-Founder

Similar to Two River

RiverVestSt. Louis, MO, USest. 2000RiverVestSt. Louis, MO, US · est. 2000

RiverVest Venture Partners®: A venture capital firm shaping early-stage life science companies for shareholder value.

Investment Firm36

WestRiver GroupSeattle, WA, USest. 2002WestRiver GroupSeattle, WA, US · est. 2002

WestRiver Group: A global investment firm specializing in tech, life sciences, energy, and experiential sectors.

Investment Firm123

Riveria Investment GroupNew York City, NY, USest. 2012Riveria Investment GroupNew York City, NY, US · est. 2012

Riveria Investment Group: A US-based private equity firm specializing in diverse sector investments.

Investment Firm12

RTW Venture FundNew York City, NY, USest. 2019RTW Venture FundNew York City, NY, US · est. 2019

NY-based RTW Biotech Opportunities Ltd invests in high-growth life sciences and med-tech innovations.

Investment Firm2

Leadership at UroGen Pharma

Stuart HoldenBoard Member

Kate FalbergBoard Member

Cynthia ButittaBoard Member

Shawn TomaselloBoard Member

Fred E. CohenBoard Member

Asher HolzerFounder

Similar to UroGen Pharma

Aytu BioPharmaEnglewood, CO, USPharmaceuticals, Therapeuticsest. 2015Aytu BioPharmaEnglewood, CO, US · est. 2015

Aytu BioPharma: A global specialty healthcare firm focusing on urological disorders and male infertility.

Public · $36M164

Leadership at Kronos Bio

Norbert BischofbergerBoard Member

Elena RidloffBoard Member

Otello StampacchiaBoard Member

Angela KoehlerCo-Founder

Marianne De BackerBoard Member

Similar to Kronos Bio

Clovis OncologyBoulder, CO, USCancer Treatmentsest. 2009Clovis OncologyBoulder, CO, US · est. 2009

Clovis Oncology, a global biotech firm, specializes in developing and commercializing cancer treatments.

Public · $145M413

Recent news

Ginkgo Bioworks Reports First Quarter 2026 Financial Results, Completes Divestiture of Biosecurity and Continues to Scale Autonomous LabPR Newswire · 2026

Ginkgo Bioworks Reports Fourth Quarter and Full Year 2025 Financial Results, Announces Focus on Autonomous Labs Offerings and Divestiture of Its Non-Core Biosecurity BusinessPR Newswire · 2026

NeuImmune and Ginkgo Bioworks Launch Strategic Collaboration to Accelerate Precision BiologicsNeuImmune · 2025

Leadership at Ginkgo Bioworks

Reshma ShettyPresident

Austin CheHead of Strategy

Barry CantonChief Technology Officer

Similar to Ginkgo Bioworks

Prolific MachinesEmeryville, CA, USCell Manufacturingest. 2020Prolific MachinesEmeryville, CA, US · est. 2020

Prolific Machines develops a light-controlled platform that programs living cells to manufacture therapeutic proteins and other bioproducts.

Series B · $197M67

Alaunos TherapeuticsHouston, TX, USCancer Treatmentest. 2005Alaunos TherapeuticsHouston, TX, US · est. 2005

Alaunos Therapeutics: A global clinical-stage company specializing in TCR-T cell therapy for solid tumors.

Public · $293.4M34

Atara BiotherapeuticsSouth San Francisco, CA, UST-Cell Therapiesest. 2012Atara BiotherapeuticsSouth San Francisco, CA, US · est. 2012

Atara Biotherapeutics: A clinical-stage biotech firm dedicated to developing therapies for severe diseases.

Public · $499.8M334

ImmuneBridgeSan Francisco, CA, USCancer Therapiesest. 2018ImmuneBridgeSan Francisco, CA, US · est. 2018

ImmuneBridge pioneers in developing allogeneic immunotherapies for cancer using cord blood-derived stem cells.

Urica TherapeuticsBay Harbor Islands, FL, USPharmaceuticalsest. 2021

Urica TherapeuticsBay Harbor Islands, FL, US · est. 2021

Urica Therapeutics, a Fortress Biotech subsidiary, develops pharmaceuticals for gout and kidney diseases.

Seed · $2.5M5

UrogpoRocky River, OH, USPharmaceuticals, Purchasing Contractsest. 2013UrogpoRocky River, OH, US · est. 2013

UroGPO: A pharmaceutical firm offering pre-negotiated purchasing contracts and revenue development.

Seed · $1.9M75

Uro-1Winston-Salem, NC, USMedical Devicesest. 2017Uro-1Winston-Salem, NC, US · est. 2017

URO-1: Innovating urology and urogynecology with breakthrough office-based medical devices.

Series A · $4.1M7

QronoPittsburgh, PA, USCancer Therapiesest. 2010

QronoPittsburgh, PA, US · est. 2010

Qrono, Inc., a Pittsburgh-based biotech company, specializes in developing cancer tumor therapies.

Angel · $50k8

Revolution MedicinesRedwood City, CA, USOncology Therapiesest. 2014Revolution MedicinesRedwood City, CA, US · est. 2014

US-based Revolution Medicines, Inc. discovers novel oncology therapies targeting elusive growth pathways globally.

Public · $1.1B246

ImageneBioBoston, MA, USCancer Therapiesest. 2016ImageneBioBoston, MA, US · est. 2016

Ikena: A targeted oncology firm developing novel therapies to combat cancer's formation and spread.

Public · $209M68

Shyam SankarChairman

Harry Evans SloanBoard Member

Tom KnightFounder

StrateosMenlo Park, CA, USLab Automation, Researchest. 2019

StrateosMenlo Park, CA, US · est. 2019

Strateos: A data-driven life science company advancing research efficiency through automation and robotics.

Series B · $105.8M83

CodexisRedwood City, CA, USEnzyme Developmentest. 2002CodexisRedwood City, CA, US · est. 2002

Protein engineering company delivering enzymatic solutions for RNA and pharma manufacturing.

Public · $162M248

Culture BiosciencesSan Francisco, CA, USBioreactors, Softwareest. 2016Culture BiosciencesSan Francisco, CA, US · est. 2016

Culture Biosciences: Automated bio-reactors for biotech, enhancing product development and market speed.

Series C · $101.6M104